Raimund Weitgasser
Overview
Explore the profile of Raimund Weitgasser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
1226
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kietaibl A, Schutz-Fuhrmann I, Bozkurt L, Fruhwald L, Rami-Merhar B, Frohlich-Reiterer E, et al.
Wien Klin Wochenschr
. 2024 Aug;
136(Suppl 9):467-477.
PMID: 39196351
People living with diabetes mellitus can be supported in the daily management by diabetes technology with automated insulin delivery (AID) systems to reduce the risk of hypoglycemia and improve glycemic...
2.
Secco K, Baumann P, Pottler T, Aberer F, Cigler M, Elsayed H, et al.
Sensors (Basel)
. 2024 Jul;
24(14).
PMID: 39065912
Objective: The aim of this analysis was to assess glycemic control before and during the coronavirus disease (COVID-19) pandemic. Methods: Data from 64 (main analysis) and 80 (sensitivity analysis) people...
3.
Toplak H, Bilitou A, Alber H, Auer J, Clodi M, Ebenbichler C, et al.
Wien Klin Wochenschr
. 2023 Jun;
135(13-14):364-374.
PMID: 37286910
Objective: The low-density lipoprotein cholesterol goals in the 2019 European Society of Cardiology/European Atherosclerosis Society dyslipidaemia guidelines necessitate greater use of combination therapies. We describe a real-world cohort of patients...
4.
Weitgasser R, Ciardi C, Traub J, Barta M, Riedl M, Clodi M, et al.
Wien Klin Wochenschr
. 2023 Apr;
135(Suppl 1):137-142.
PMID: 37101034
Diabetes education and self-management play a critical role in diabetes care. Patient empowerment aims to actively influence the course of the disease by self-monitoring and subsequent treatment modification as well...
5.
Kautzky-Willer A, Winhofer Y, Weitgasser R, Lechleitner M, Harreiter J
Wien Klin Wochenschr
. 2023 Apr;
135(Suppl 1):129-136.
PMID: 37101033
In 1989 the St. Vincent Declaration aimed to achieve comparable pregnancy outcomes in women with diabetes and those with normal glucose tolerance. However, currently women with pre-gestational diabetes still feature...
6.
Kautzky-Willer A, Winhofer Y, Kiss H, Falcone V, Berger A, Lechleitner M, et al.
Wien Klin Wochenschr
. 2023 Apr;
135(Suppl 1):115-128.
PMID: 37101032
Gestational diabetes (GDM) is defined as any degree of glucose intolerance with onset during pregnancy and is associated with increased feto-maternal morbidity as well as long-term complications in mothers and...
7.
Lechleitner M, Kaser S, Hoppichler F, Roden M, Weitgasser R, Ludvik B, et al.
Wien Klin Wochenschr
. 2023 Apr;
135(Suppl 1):98-105.
PMID: 37101030
This guideline summarizes diagnosis of type 1 diabetes, including accompanying autoimmune disorders, insulin therapy regimens and glycemic target values.
8.
Francesconi C, Niebauer J, Haber P, Moser O, Weitgasser R, Lackinger C
Wien Klin Wochenschr
. 2023 Apr;
135(Suppl 1):78-83.
PMID: 37101027
Lifestyle, in general and particularly regular physical activity, is known to be an important component in the prevention and therapy of type 2 diabetes.To gain substantial health benefits, a minimum...
9.
Schutz-Fuhrmann I, Rami-Merhar B, Frohlich-Reiterer E, Hofer S, Tauschmann M, Mader J, et al.
Wien Klin Wochenschr
. 2023 Apr;
135(Suppl 1):53-61.
PMID: 37101025
This Guideline represents the recommendations of the Austrian Diabetes Association (ÖDG) on the use of diabetes technology (insulin pump therapy; continuous glucose monitoring, CGM; hybrid closed-loop systems, HCL; diabetes apps)...
10.
Lechleitner M, Roden M, Weitgasser R, Ludvik B, Fasching P, Hoppichler F, et al.
Wien Klin Wochenschr
. 2023 Apr;
135(Suppl 1):45-52.
PMID: 37101024
The present article is a recommendation of the Austrian Diabetes Association for the practical use of injection therapy (GLP1-receptor agonists and insulin) in type 2 diabetes.